Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Keros Therapeutics (KROS) EBIAT (2019 - 2025)

Keros Therapeutics filings provide 7 years of EBIAT readings, the most recent being -$23.5 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 49.03% to -$23.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $87.0 million, a 146.44% increase, with the full-year FY2025 number at $87.0 million, up 146.44% from a year prior.
  • EBIAT hit -$23.5 million in Q4 2025 for Keros Therapeutics, down from -$7.3 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $148.5 million in Q1 2025 to a low of -$53.0 million in Q3 2024.
  • Median EBIAT over the past 5 years was -$28.5 million (2022), compared with a mean of -$20.8 million.
  • Biggest five-year swings in EBIAT: plummeted 328.21% in 2022 and later soared 444.32% in 2025.
  • Keros Therapeutics' EBIAT stood at -$6.9 million in 2021, then plummeted by 328.21% to -$29.7 million in 2022, then crashed by 35.42% to -$40.2 million in 2023, then decreased by 14.37% to -$46.0 million in 2024, then surged by 49.03% to -$23.5 million in 2025.
  • The last three reported values for EBIAT were -$23.5 million (Q4 2025), -$7.3 million (Q3 2025), and -$30.7 million (Q2 2025) per Business Quant data.